Complement activation and effect of eculizumab in scleroderma renal crisis

Medicine (United States)

Volumn 95, Issue 30, 2016, Pages

  Devresse, Arnaud ^a,b   Aydin, Selda ^a,b   Le Quintrec, Moglie ^c   Demoulin, Nathalie ^a,b   Stordeur, Patrick ^d   Lambert, Catherine ^a   Gastoldi, Sara ^e   Pirson, Yves ^a,b   Jadoul, Michel ^a,b   Morelle, Johann ^a,b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c LAPEYRONIE HOSPITAL   (France)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

acute kidney injury; complement system; systemic sclerosis; thrombotic microangiopathy

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; HEMOGLOBIN; LACTATE DEHYDROGENASE; LISINOPRIL; NICARDIPINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ACUTE KIDNEY FAILURE; ADULT; ARTERIOLE; ARTERY ENDOTHELIUM; ARTICLE; CASE REPORT; CESAREAN SECTION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; FETUS DISTRESS; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY ARTERY; KIDNEY BIOPSY; LIVER FUNCTION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; SCLERODERMA; SCLERODERMA RENAL CRISIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TWIN PREGNANCY; ACUTE KIDNEY INJURY; ANTAGONISTS AND INHIBITORS; BIOPSY; COMPLEMENT CLASSICAL PATHWAY; DRUG EFFECTS; FATALITY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; KIDNEY; MULTIPLE PREGNANCY; NEWBORN; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; SCLERODERMA, SYSTEMIC; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ACUTE KIDNEY INJURY; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C4B; COMPLEMENT C5; COMPLEMENT PATHWAY, CLASSICAL; ENDOTHELIUM, VASCULAR; FATAL OUTCOME; FEMALE; HUMANS; INFANT, NEWBORN; KIDNEY; MICROSCOPY, FLUORESCENCE; PEPTIDE FRAGMENTS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY, MULTIPLE; SCLERODERMA, SYSTEMIC;

EID: 84982804500     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004459     Document Type: Article

References (26)

1. Mouthon L, Bussone G, Berezné A, et al. Scleroderma renal crisis. J Rheumatol 2014;41:1040-8.
2. Denton CP, Lapadula G, Mouthon L, et al. Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 2009;48(suppl 3): iii32-5.
3. Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014;124:1715-26.
4. Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 2010;28:S48-53.
5. Frémeaux-Bacchi V, Legendre CM. The emerging role of complement inhibitors in transplantation. Kidney Int 2015;88:967-73.
6. Hudson M, Walker JG, Fritzler M, et al. Hypocomplementemia in systemic sclerosis-clinical and serological correlations. J Rheumatol 2007;34:2218-23.
7. Cuomo G, Abignano G, Ruocco L, et al. Hypocomplementemia in systemic sclerosis. Reumatismo 2008;60:268-73.
8. Scambi C, Ugolini S, Jokiranta TS, et al. The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesisgenerating study. PLoS One 2015;10:e0114856.
9. Batal I, Domsic RT, Shafer A, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009;40: 332-40.
10. Cataland SR, Holers VM, Geyer S, et al. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 2014;123:3733-8.
11. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-59.
12. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676-87.
13. Wild G, Watkins J, Ward AM, et al. Complement activation in systemic sclerosis. J Clin Lab Immunol 1990;31:39-41.
14. Arason GJ, Geirsson AJ, Kolka R, et al. Deficiency of complementdependent prevention of immune precipitation in systemic sclerosis. Ann Rheum Dis 2002;61:257-60.
15. Ballanti E, Perricone C, Greco E, et al. Complement and autoimmunity. Immunol Res 2013;56:477-91.
16. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991;86:464-70.
17. Cohen D, Koopmans M, Kremer Hovinga IC, et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 2008;58:2460-9.
18. Shen Y, Chen XW, Sun CY, et al. Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus 2010;19:1195-203.
19. Li SJ, Liu ZH, Zen CH, et al. Peritubular capillary C4d deposition in lupus nephritis different from antibody-mediated renal rejection. Lupus 2007;16:875-80.
20. Yin W, Ghebrehiwet B, Weksler B, et al. Regulated complement deposition on the surface of human endothelial cells: effect of tobacco smoke and shear stress. Thromb Res 2008;122:221-8.
21. Wilson MR, Arroyave CM, Nakamura RM, et al. Activation of the alternative complement pathway in systemic lupus erythematosus. Clin Exp Immunol 1976;26:11-20.
22. Thomas CP, Nester CM, Phan AC, et al. Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome. Clin Kidney J 2015;8:698-701.
23. Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolyticuremic syndrome. N Engl J Med 2013;369:1379-80.
24. Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc 2013;45:1022-5.
25. PickeringMC, IsmajliM, CondonMB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 2015;54:2286-8.
26. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015;65:127-30.